Neuren PharmaceuticalsASX:NEU -4.39%54 Quick Ratio is 76.60 as of Dec. 2025, which is 290% above its 10-year median of 19.65. GuruFocus rates ASX:NEU with a GF Score™ of 54/100 and a GF Value™ of A$6.08 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Neuren Pharmaceuticals ranks better than 99.44% on this metric.
Neuren Pharmaceuticals has a quick ratio of 76.60. It generally indicates good short-term financial strength.
The historical rank and industry rank for Neuren Pharmaceuticals's Quick Ratio or its related term are showing as below:
ASX:NEU'
s Quick Ratio Range Over the Past 10 Years
Min: 2.99 Med: 19.65 Max: 76.6
Current: 76.6
During the past 13 years, Neuren Pharmaceuticals's highest Quick Ratio was 76.60. The lowest was 2.99. And the median was 19.65.
ASX:NEU's Quick Ratio is ranked better than 99.44% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:NEU: 76.60
Neuren Pharmaceuticals (ASX:NEU) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Neuren Pharmaceuticals Quick Ratio Related Terms
Neuren Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NEU vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Neuren Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a Quick Ratio of 76.60 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Neuren Pharmaceuticals and its competitors. This is 290% above median its historical median of 19.65. Over the past decade, Neuren Pharmaceuticals' Quick Ratio has ranged from 2.99 to 76.60. According to the industry distribution chart, Neuren Pharmaceuticals ranks #8 out of 1416 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Neuren Pharmaceuticals' Quick Ratio too high?
Neuren Pharmaceuticals' current Quick Ratio of 76.60 is 290% above median its 10-year median of 19.65. Over the past 10 years, this metric has ranged from a low of 2.99 to a high of 76.60. The Biotechnology industry median Quick Ratio is 3.60. Neuren Pharmaceuticals' value of 76.60 is 2027.8% above this industry median. Based on the distribution chart, Neuren Pharmaceuticals ranks #8 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #8 out of 1416 companies for Quick Ratio. This places Neuren Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Neuren Pharmaceuticals' value of 76.60 is 2027.8% above this benchmark. Historically, Neuren Pharmaceuticals' own Quick Ratio has ranged from 2.99 to 76.60 over the past decade. While the company's 10-year median is 19.65 vs. the industry median of 3.60, Neuren Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuren Pharmaceuticals's current Quick Ratio of 76.60 is 2027.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Neuren Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current Quick Ratio is 76.60, which is 290% above median its own 10-year median of 19.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$6.08, compared to a current price of A$12.20 — trading 100.7% above its estimated fair value. The current Quick Ratio is 76.60, which is 290% above median its 10-year median of 19.65 and 2027.8% above the Biotechnology industry median of 3.60. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Quick Ratio is 76.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$12.20 is trading 100.7% above its estimated GF Value™ of A$6.08.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
Quick Ratio: 76.60 (290% above median its 10-year median of 19.65)
GF Value™: A$6.08 vs. price of A$12.20 (100.7% above fair value)
Industry Position: 2027.8% above the Biotechnology median (#8 of 1416)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score
Get the complete analysis for ASX:NEU
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
